The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite

Multiple Sclerosis

Volumn 10, Issue 1, 2004, Pages 55-60

  Hoogervorst, E L J ^a   Kalkers, N F ^a   Cutter, G R ^c   Uitdehaag, B M J ^a,b   Polman, C H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

GNDS; Longitudinal study; MS; MSFC

Indexed keywords

ARTICLE; CORRELATION ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; GUY NEUROLOGICAL DISABILITY SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; OUTPATIENT DEPARTMENT; PATIENT ATTITUDE; PHYSICAL DISABILITY; PREVALENCE; PROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; OUTPATIENTS; PROSPECTIVE STUDIES; SELF CONCEPT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0346707263     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms972oa     Document Type: Article

References (18)

1. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
2. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-82.
3. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996; 40: 469-79.
4. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: Relationship to patient-reported quality of life. Arch Neurol 2000; 57: 1319-24.
5. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
6. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): A new disability measure for multiple sclerosis. Mult Scler 1999; 5: 223-33.
7. Sharrack B, Hughes RA. Scale development and Guy's Neurological Disability Scale. J Neurol 1999; 246: 226 (letter).
8. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
11. Kalkers NF, de Groot G, Lazeron RH, Killestein J, Ader HJ, Barkhof F et al. MS functional composite: Relation to disease phenotype and disability strata. Neurology 2000; 54: 1233-39.
12. Cohen JA, Fischer JS, Bolibrush DM, Jak AJ, Kniker JE, Mertz LA et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000; 54: 802-806.
13. Hoogervorst ELJ, van Winsen LM, Eikelenboom MJ, Kalkers NF, Uitdehaag BMJ, Polman CH. Comparisons of patient self-report, neurologic examination, and functional impairment in MS. Neurology 2001; 56: 934-37.
14. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: What is a reliable change? Neurology 2002; 58: 1294-96.
15. Uitdehaag BM, Ader HJ, Kalker NF, Polman CH. Quantitative functional measures in MS: What is a reliable change? Neurology 2002; 59: 648-49.
16. Schwid SR, Goodman AD, Apatoff BR. Quantitative measures are more sensitive to worsening neurological function in a prospective multiple sclerosis study. Ann Neurol 1998; 44: 483 (abstract).
17. Cohen JA, Cutter GC, Simonian SA. Utilization of the MS Functional Composite as an outcome measure in the phase 3 trial of interferon beta-1a (R/Avonex) in secondary progressive MS (IMPACT). Neurology 1999; 52(suppl 2): A548-49.
18. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(3 suppl): S178-89.